Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Hims & Hers Health, Inc. NASDAQ:HIMS Chief Financial Officer Oluyemi Okupe, sold 11,581 shares of Class A Common Stock on July 14, 2025, for approximately $552,418. The shares were sold at prices ranging from $47.46 to $47.995.
According to a Form 4 filing with the Securities and Exchange Commission, Okupe also exercised options to acquire 7,587 shares of Class A Common Stock at a price of $5.01, for a total value of $38,010.
Following the sale, Okupe directly owns 54,084 shares of Hims & Hers Health, Inc. Class A Common Stock. Additionally, Okupe indirectly owns 70,575 shares held by the Oluyemi Okupe Separate Property Trust.
The reported transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 31, 2024.
In other recent news, Hims & Hers has been in the spotlight due to several significant developments. The company recently faced the termination of its partnership with Novo Nordisk (NYSE:NVO), which ended in June 2025. This split followed disagreements over Hims’ sale of compounded semaglutide, leading to allegations from Novo Nordisk of illegal sales and deceptive marketing practices. Despite these challenges, Hims & Hers continues to offer Wegovy at retail prices on its platform.
In terms of expansion, Hims & Hers announced plans to launch its weight loss program in Canada in 2026, aligning with the availability of generic semaglutide in that market. This move is part of the company’s broader international growth strategy and follows its acquisition of Zava. The expansion aims to provide Canadians with access to lower-cost alternatives to branded medications.
On the analyst front, Morgan Stanley (NYSE:MS) has maintained its Equalweight rating for Hims & Hers, noting a slowdown in app download growth but recognizing the company’s international expansion efforts. Meanwhile, Citi has reiterated a Sell rating, highlighting concerns about pricing opportunities in the Canadian market. Leerink Partners also maintained a Market Perform rating, suggesting the Canadian expansion could drive incremental revenue by 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.